ZA200900477B - Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors - Google Patents

Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors

Info

Publication number
ZA200900477B
ZA200900477B ZA200900477A ZA200900477A ZA200900477B ZA 200900477 B ZA200900477 B ZA 200900477B ZA 200900477 A ZA200900477 A ZA 200900477A ZA 200900477 A ZA200900477 A ZA 200900477A ZA 200900477 B ZA200900477 B ZA 200900477B
Authority
ZA
South Africa
Prior art keywords
oxazolopyridines
benzoxazoles
useful
janus kinases
kinases inhibitors
Prior art date
Application number
ZA200900477A
Other languages
English (en)
Inventor
Mar Gerspacher
Pascal Furet
Eric Vangrevelinghe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200900477(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200900477B publication Critical patent/ZA200900477B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200900477A 2006-09-15 2009-01-21 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors ZA200900477B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (de) 2006-09-15 2006-09-15 Benzoxazole und Oxazolopyridine und ihre Verwendung als Inhibitoren von Janus-Kinasen

Publications (1)

Publication Number Publication Date
ZA200900477B true ZA200900477B (en) 2010-01-27

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900477A ZA200900477B (en) 2006-09-15 2009-01-21 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors

Country Status (30)

Country Link
US (1) US8629168B2 (de)
EP (2) EP1900729A1 (de)
JP (1) JP5325105B2 (de)
KR (1) KR20090064389A (de)
CN (1) CN101516860B (de)
AR (1) AR062786A1 (de)
AT (1) ATE532774T1 (de)
AU (1) AU2007296916B2 (de)
BR (1) BRPI0716841A2 (de)
CA (1) CA2660987A1 (de)
CL (1) CL2007002669A1 (de)
CO (1) CO6150142A2 (de)
CR (1) CR10639A (de)
EA (1) EA200900388A1 (de)
ES (1) ES2377148T3 (de)
GT (1) GT200900056A (de)
IL (1) IL196860A0 (de)
MA (1) MA30723B1 (de)
MX (1) MX2009002812A (de)
NO (1) NO20091469L (de)
PA (1) PA8748101A1 (de)
PE (1) PE20080842A1 (de)
PL (1) PL2066647T3 (de)
PT (1) PT2066647E (de)
SM (1) SMP200900023B (de)
TN (1) TN2009000070A1 (de)
TW (1) TW200819444A (de)
UY (1) UY30587A1 (de)
WO (1) WO2008031594A1 (de)
ZA (1) ZA200900477B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
KR20110042286A (ko) * 2008-07-15 2011-04-26 사노피-아벤티스 Ｅｄｇ－１ 수용체 작용제로서의 옥사졸로피리미딘
US20100041891A1 (en) * 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
AU2009320683B2 (en) 2008-11-28 2012-07-19 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
WO2011078360A1 (ja) 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
UY33176A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2, 5, 7.
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
WO2015117147A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
US9394236B2 (en) 2014-02-03 2016-07-19 Quadriga Biosciences, Inc. β-substituted γ-amino acids and analogs as chemotherapeutic agents
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
CA2994404C (en) 2015-08-03 2020-12-08 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022251597A1 (en) 2021-05-28 2022-12-01 Verge Analytics, Inc. Methods of treating neurological disorders with modulators of ribosomal protein s6 kinase alpha-1 (rsk1) and ribosomal protein s6 kinase alpha-3 (rsk2)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006227B1 (ru) * 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (de) * 2004-12-22 2006-06-28 4Sc Ag 2,5- und 2,6-disubstituierte Benzazol-Derivate zur Verwendung als Protein Kinase Inhibitoren
KR101047221B1 (ko) * 2005-09-02 2011-07-06 에프. 호프만-라 로슈 아게 벤조옥사졸, 옥사졸로피리딘, 벤조싸이아졸 및싸이아졸로피리딘 유도체
CA2657260A1 (en) * 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors

Also Published As

Publication number Publication date
US20100009978A1 (en) 2010-01-14
AU2007296916B2 (en) 2011-10-06
ATE532774T1 (de) 2011-11-15
PA8748101A1 (es) 2009-08-26
CO6150142A2 (es) 2010-04-20
PT2066647E (pt) 2012-01-17
MA30723B1 (fr) 2009-09-01
PL2066647T3 (pl) 2012-04-30
BRPI0716841A2 (pt) 2013-10-01
GT200900056A (es) 2011-11-08
CR10639A (es) 2009-07-03
MX2009002812A (es) 2009-03-31
IL196860A0 (en) 2009-11-18
TN2009000070A1 (en) 2010-08-19
CN101516860B (zh) 2012-06-27
KR20090064389A (ko) 2009-06-18
EP1900729A1 (de) 2008-03-19
SMAP200900023A (it) 2009-05-11
CN101516860A (zh) 2009-08-26
EP2066647A1 (de) 2009-06-10
CL2007002669A1 (es) 2008-05-09
US8629168B2 (en) 2014-01-14
AR062786A1 (es) 2008-12-03
AU2007296916A1 (en) 2008-03-20
EP2066647B1 (de) 2011-11-09
WO2008031594A1 (en) 2008-03-20
JP2010503629A (ja) 2010-02-04
CA2660987A1 (en) 2008-03-20
JP5325105B2 (ja) 2013-10-23
EA200900388A1 (ru) 2009-08-28
PE20080842A1 (es) 2008-08-11
ES2377148T3 (es) 2012-03-22
TW200819444A (en) 2008-05-01
NO20091469L (no) 2009-04-15
SMP200900023B (it) 2009-07-14
UY30587A1 (es) 2008-05-02

Similar Documents

Publication Publication Date Title
IL196860A0 (en) Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors
IL284889A (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
ZA200808536B (en) Deazapurines useful as inhibitors of janus kinases
ZA201004055B (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
ZA200805053B (en) Azaindoles useful as inhibitors of janus kinases
ZA200802685B (en) Deazapurines useful as inhibitors of janus kinases
IL192634A0 (en) Thiazoles as 11 beta-hsd1 inhibitors
GB0619753D0 (en) Enzyme inhibitors
SI1910348T1 (sl) Spojine benzotiazola in azabenzotiazola, uporabne kot kinazni inhibitorji
EP2166846A4 (de) Januskinase-hemmer
IL194699A0 (en) Tetrahydropteridines useful as inhibitors of protein kinases
EP2231143A4 (de) Janus-kinasehemmer
IL194339A0 (en) Enzyme inhibitors
EP2032141A4 (de) Januskinase-hemmer
EP2200612A4 (de) Januskinase-hemmer
ZA200806871B (en) Dihydrodiazepines useful as inhibitors of protein kinases
ZA200902091B (en) Serine hydrolase inhibitors
ZA200900907B (en) Pyrimidine derivative as P13K inhibitor and use thereof
GB0608844D0 (en) Enzyme inhibitors
GB0617161D0 (en) Enzyme inhibitors
HK1131393A (en) Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors
GB0612544D0 (en) Enzyme inhibitors
ZA200808237B (en) Enzyme inhibitors
GB0624958D0 (en) Enzyme inhibitors
GB0620884D0 (en) Enzyme inhibitors